• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎何时需要全身治疗?国际特应性皮炎理事会专家小组的建议。

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.

机构信息

Department of Dermatology, Oregon Health and Science University, Portland, Oregon.

National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

J Am Acad Dermatol. 2017 Oct;77(4):623-633. doi: 10.1016/j.jaad.2017.06.042. Epub 2017 Aug 10.

DOI:10.1016/j.jaad.2017.06.042
PMID:28803668
Abstract

BACKGROUND

Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking.

OBJECTIVE

To guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient.

METHODS

A subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion.

RESULTS

We recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy.

LIMITATIONS

Our work is a consensus statement, not a systematic review.

CONCLUSION

The decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.

摘要

背景

尽管大多数特应性皮炎(AD)患者通过局部药物治疗即可得到有效管理,但仍有相当一部分患者需要接受系统治疗。目前缺乏关于推进系统治疗决策的指南。

目的

为考虑使用 AD 系统治疗的患者提供指导,并在与患者做出这一治疗决策之前,为评估提供框架。

方法

国际特应性皮炎理事会的一个小组确定了在开具全身治疗药物之前需要考虑的方面。将主题分配给专家评审员,由他们进行特定主题的文献回顾,参考现有指南,并提供解释和专家意见。

结果

我们建议在开始全身治疗之前,采用系统和整体的方法来评估患有严重 AD 体征和症状以及对生活质量有影响的患者。在开始全身治疗之前采取的措施包括考虑其他或同时存在的诊断、避免触发因素、优化局部治疗、确保患者/照顾者得到充分教育、治疗并存的感染、评估对生活质量的影响以及考虑光疗。

局限性

我们的工作是一项共识声明,而非系统评价。

结论

开始全身药物治疗的决定应包括评估严重程度和生活质量,同时考虑个体的整体健康状况、心理需求以及对全身治疗的个人态度。

相似文献

1
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.特应性皮炎何时需要全身治疗?国际特应性皮炎理事会专家小组的建议。
J Am Acad Dermatol. 2017 Oct;77(4):623-633. doi: 10.1016/j.jaad.2017.06.042. Epub 2017 Aug 10.
2
Guidelines for the Management of Atopic Dermatitis in Singapore.新加坡特应性皮炎管理指南。
Ann Acad Med Singap. 2016 Oct;45(10):439-450.
3
Long-Term Treatment of Atopic Dermatitis.特应性皮炎的长期治疗
Dermatol Clin. 2017 Jul;35(3):335-349. doi: 10.1016/j.det.2017.02.007. Epub 2017 May 6.
4
[Not Available].[不可用]。
Ann Dermatol Venereol. 2019 Dec;146(12S3):12S76-12S84. doi: 10.1016/S0151-9638(20)30017-X.
5
An update on the topical and oral therapy options for treating pediatric atopic dermatitis.治疗儿童特应性皮炎的局部和口服治疗选择的最新进展。
Expert Opin Pharmacother. 2019 Apr;20(5):621-629. doi: 10.1080/14656566.2018.1561868. Epub 2019 Jan 2.
6
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.光疗和系统治疗成人特应性皮炎管理的指南。
J Am Acad Dermatol. 2024 Feb;90(2):e43-e56. doi: 10.1016/j.jaad.2023.08.102. Epub 2023 Nov 7.
7
Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis).意大利特应性皮炎治疗指南——改编自基于共识的欧洲特应性皮炎治疗指南(特应性皮炎)。
Dermatol Ther. 2019 Nov;32(6):e13121. doi: 10.1111/dth.13121. Epub 2019 Nov 7.
8
Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema.低剂量甲氨蝶呤疗法对迟发性特应性皮炎和特发性湿疹有效。
Isr Med Assoc J. 2008 Jun;10(6):413-4.
9
Atopic dermatitis: phototherapy and systemic therapy.特应性皮炎:光疗与全身治疗。
Semin Cutan Med Surg. 2017 Sep;36(3):118-123. doi: 10.12788/j.sder.2017.027.
10
Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.《2016年特应性皮炎管理临床实践指南》
J Dermatol. 2016 Oct;43(10):1117-1145. doi: 10.1111/1346-8138.13392.

引用本文的文献

1
Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.特应性皮炎的管理:从传统疗法到生物标志物驱动的治疗方法。
Biomol Ther (Seoul). 2025 Sep 1;33(5):813-829. doi: 10.4062/biomolther.2025.081. Epub 2025 Aug 19.
2
Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy.韩国特应性皮炎治疗的基于共识的指南(第一部分):基础治疗、局部治疗和传统全身治疗。
Ann Dermatol. 2025 Aug;37(4):201-215. doi: 10.5021/ad.24.153.
3
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies.
加拿大外用疗法治疗特应性皮炎的共识指南。
Dermatol Ther (Heidelb). 2025 Jun;15(6):1467-1485. doi: 10.1007/s13555-025-01386-2. Epub 2025 Apr 25.
4
An Overview of Atopic Dermatitis Disease Burden, Pathogenesis, and the Current Treatment Landscape: Recommendations for Appropriate Utilization of Systemic Therapies.特应性皮炎的疾病负担、发病机制及当前治疗概况:关于合理使用全身治疗的建议
J Clin Aesthet Dermatol. 2025 Mar;18(3):51-66.
5
A case of systemic contact dermatitis associated with a peritoneal dialysis catheter and treated with dupilumab.一例与腹膜透析导管相关的系统性接触性皮炎,采用度普利尤单抗治疗。
CEN Case Rep. 2025 Jun;14(3):450-454. doi: 10.1007/s13730-025-00980-9. Epub 2025 Mar 7.
6
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study.乌帕替尼在吸烟的中度至重度特应性皮炎患者中的安全性和有效性:一项为期2年的真实世界多中心研究。
Am J Clin Dermatol. 2025 May;26(3):425-435. doi: 10.1007/s40257-025-00926-y. Epub 2025 Feb 24.
7
Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus.基层医疗中儿童及青少年特应性皮炎的管理:美国专家小组共识
J Pediatr Clin Pract. 2024 Jul 10;14:200121. doi: 10.1016/j.jpedcp.2024.200121. eCollection 2024 Dec.
8
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database.芦可替尼乳膏起始治疗前后的特应性皮炎治疗:美国医保支付方索赔数据库的6个月随访分析
Clinicoecon Outcomes Res. 2025 Feb 6;17:69-77. doi: 10.2147/CEOR.S506043. eCollection 2025.
9
Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era.胸腺与激活调节趋化因子(CCL17)作为特应性皮炎的临床生物标志物:新治疗时代的意义与局限性
Front Allergy. 2025 Jan 23;5:1473902. doi: 10.3389/falgy.2024.1473902. eCollection 2024.
10
Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis.度普利尤单抗、甲氨蝶呤和环孢素A在儿童特应性皮炎中的药物留存率
JAMA Dermatol. 2025 Jan 1;161(1):12-21. doi: 10.1001/jamadermatol.2024.3717.